FluxWorks, a hardtech startup, opened its new home-base in Conroe, Texas. Photo courtesy FluxWorks

FluxWorks, a hardtech startup, recently opened its new base of operations in Workhub Developments’ Conroe location.

Founded in College Station by CEO Bryton Praslicka, FluxWorks specializes in making contactless magnetic gears for use in extreme conditions. At 9,000 square feet, the new Conroe facility is a result of discussions with Governor Greg Abbott's office and the Greater Houston Partnership, who introduced the company’s leadership to the Conroe Economic Development Council, encouraging their move, Praslicka tells InnovationMap.

“The pieces of the puzzle were all there, and with the support of the local, state, and federal government, we were thrilled to move to Conroe,” Paslicka says.

CEO Bryton Praslicka founded the company in College Station. Photo courtesy FluxWorks

The enterprise recently won the MassChallenge’s technology in space prize, allowing them to test four gears at the International Space Station (ISS) National Laboratory in 2026. The prize is funded by Boeing and the Center for the Advancement of Science in Space, or CASIS which runs the ISS. Praslicka says their new offices will expand their manufacturing capacity by having all levels of production on-site.

"Since our inception, FluxWorks has been fragmented, having an office in one location, manufacturing in another location, and testing in a third location," Praslicka explains. "This is a new chapter for us to begin having the entire process, from design to testing and validation and then shipping to customers, all under one house.”

The magnetic gears FluxWorks makes are suited to space applications because they do not require lubricants, which can be difficult to control at harsh temperatures and in microgravity, to minimize friction. Through their partnership with the ISS, Praslicka says FluxWorks has strengthened their connections to other space tech companies including Axiom and Boeing, and it's opened the door to collaborations with the new Texas Space Commission.

“Now the NASA Johnson Space Center is even officially supporting our proposal to the Texas Space Commission as a proposed teaming partner,” Praslicka says.

The new facility received special security certification from the National Institute of Standards and Technology, increasing FluxWorks’ opportunities to work with NASA and defense contractors. The Texas Manufacturing Assistance Center awarded FluxWorks for “outstanding innovation” during its recent ribbon cutting ceremony.

The company, named a finalist for the 2024 Houston Innovation Awards, cleaned up in the 2023 Rice Business Plan Competition with a $350,000 investment prize from Houston group, Goose Capital.

FluxWorks has moved into its 9,000-square-foot facility in Conroe. Photo courtesy FluxWorks

At a research facility just outside of Houston, scientists have found a plant that has COVID-19 treatment potential. Photo courtesy of iBio

Houston-area company is harvesting plant technology for treatment of chronic diseases and COVID-19

growing a cure

The original version of this story included some factual inaccuracies due to misinformation from a source. The story below has been corrected.

In a 130,000 square-foot facility outside of Bryan-College Station, iBio is growing the makings of new types of therapeutics for fibrosis, cancer, and even COVID-19.

The company, which moved its headquarters from New York to Texas in July, uses novel biopharma methods to produce the vital molecules and antigens used for vaccines and other types of medical treatments through plants in a fast, sustainable way.

Other methods of creating biopharmaceutical require scientists to engineer cells to create a desired protein, which can be one of the most time consuming parts of the process, IBio's CEO Tom Isett explains. However, through iBio's FastPharming method, the team let's the plants do most of the work.

IBio introduces an Agrobacterium carrying a desired gene to manipulate the plant's DNA.

"[The bacteria] takes over the machinery of the plant leaves and it then produces the protein of interest or the biopharmaceutical that we were going to want to make for people," Isett says.

IBio then harvests the leaves and purifies the proteins to make the biopharmaceutical of interest. The entire process can save anywhere from six to 18 months in development, he estimates.

Too, if there's demand for more of the product, through this process, all scientists need to do is grow more plants.

"We have a linear scale up, it's very straightforward," says Peter Kipp, iBio's VP of translational science and alliance management. "And using some of the other competing methodologies, as you go to a bigger scale, you have new technical problems that you have to solve, but we don't."

The team discovered that an Australian species of the tobacco plant could be one of their biggest conduits in their process.

"It just grows like a weed. And that's why we like it," Kipp says.

The plant expends most of its energy in creating its leaves, where IBio extracts most of its proteins from. The plants are grown in the company's indoor, vertical hydroponic facility and are able to be harvested about every six weeks, and (it's important to note) does not contain nicotine.

IBio used their FastPharming process to introduce two vaccine candidates and a therapeutic in about six week's time. However, Isett says they're not just a COVID-19 vaccine company.

"We're mostly focused in other areas. But when [COVID] showed up, we did want to go in and see if we could address it using the speed of our system," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.